Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men

被引：91
作者：
Ghosn, J [1 ]
Chaix, ML
Peytavin, G
Rey, E
Bresson, JL
Goujard, C
Katlama, C
Viard, JP
Tréluyer, JM
Rouzioux, C
机构：
[1] Univ Paris 05, EA 3620, MRT, Virol Lab, F-75270 Paris 06, France
[2] CHU Necker Enfants Malad, Dept Malad Infect, F-75730 Paris, France
[3] CHU Bichat, Lab Pharmacol Clin, Paris, France
[4] CHU St Vincent Paul, Lab Pharmacol Clin, Paris, France
[5] CHU Bicetre, Le Kremlin Bicetre, France
[6] CHU Pitie Salpetriere, Dept Malad Infect, Paris, France
来源：
AIDS | 2004年 / 18卷 / 14期
关键词：
D O I：
10.1097/00002030-200409240-00014
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
One likely mechanism of virological failure is poor antiretroviral. drug diffusion in sites of viral replication such as the genital tract. We measured antiretroviral drug concentrations in blood and semen in 13 HIV-infected men failing treatment. Enfuvirtide did not cross the blood-testis barrier, whereas tenofovir accumulated in semen. Unlike indinavir, semen concentrations of lopinavir, amprenavir, saquinavir and efavirenz were ineffective. These are worrying findings, because suboptimal semen drug concentrations may enhance the risk of sexually transmitted drug-resistant HIV variants.
引用
收藏
页码：1958 / 1961
页数：4
相关论文
共 24 条
  • [1] AAMNOUTSE RE, 2001, J CHROMATOGR B, V764, P363
  • [2] Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men
    Chaudry, NI
    Eron, JJ
    Naderer, OJ
    Pereira, AS
    Wire, MB
    Fiscus, SA
    Kashuba, ADM
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 35 (06) : 760 - 762
  • [3] Coakley DF., 2001, 1 IAS C HIV PATH TRE
  • [4] Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs
    Cundy, KC
    Sueoka, C
    Lynch, GR
    Griffin, L
    Lee, WA
    Shaw, JP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) : 687 - 690
  • [5] GATHE JC, 2003, 43 ANN ICAAC C CHIC
  • [6] Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men
    Ghosn, J
    Viard, JP
    Katlama, C
    de Almeida, M
    Tubiana, R
    Letourneur, F
    Aaron, L
    Goujard, C
    Salmon, D
    Leruez-Ville, M
    Rouzioux, C
    Chaix, ML
    [J]. AIDS, 2004, 18 (03) : 447 - 457
  • [7] Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir 400 mg indinavir in HIV-infected patients
    Ghosn, J
    Lamotte, C
    Ait-Mohand, H
    Wirden, M
    Agher, R
    Schneider, L
    Bricaire, F
    Duvivier, C
    Calvez, V
    Peytavin, G
    Katlama, C
    [J]. AIDS, 2003, 17 (02) : 209 - 214
  • [8] *GLAX SMITHKL, 2001, AG PACK INS
  • [9] Ritonavir boosted indinavir treatment as a simplified maintenance 'mono'-therapy for HIV infection
    Kahlert, C
    Hupfer, M
    Wagels, T
    Bueche, D
    Fierz, W
    Walker, UA
    Vernazza, PL
    [J]. AIDS, 2004, 18 (06) : 955 - 957
  • [10] Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1
    Kashuba, ADM
    Dyer, JR
    Kramer, LM
    Raasch, RH
    Eron, JJ
    Cohen, MS
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) : 1817 - 1826
123